Dr Johansson is head of the ImmVirX quality assurance programme. She is a molecular biologist with over 20 years’ experience in the biotechnology sector. Dr Johansson, who holds a PhD in molecular virology from the University of Kalmar, Sweden, headed the quality assurance programme at Viralytics, including through its acquisition by Merck & Co., Inc. in 2018. She has extensive experience in the fundamentals of oncolytic immunotherapies and their application in both preclinical and clinical settings. Dr Johansson has performed key roles in assay development and monitoring data from laboratory assays generated by oncolytic viruses in the clinical setting.